Establishment of environmental, social and governance committee
Filed with HKEX · Stock code 1952 · · 1 page · English
Summary by 6ix AI
Everest Medicines Ltd. has established an Environmental, Social and Governance Committee, effective from a specified date in the future. The committee will consist of at least three members, with Mr. Yifang Wu appointed as chairman. The terms of reference for the committee will be published on the relevant websites.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Everest Medicines
- Next Day Disclosure Return
- Everest Medicines Announces China NMPA Approval of CARDAMYST® for the Conversion of Acute Symptomatic Episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to Sinus Rhythm in Adults
- Everest Medicines Announces Interim Results for First Half of 2026
- Everest Medicines to Announce 2026 Interim Results and Host Online Investor Call on August 19, 2026
- Everest Medicines Announces Participation in Upcoming Investor Conferences
Later from Everest Medicines
- List of directors and their roles and functions
- Terms of reference of the environmental, social and governance committee
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development
- Book closure period for extraordinary general meeting
Follow Everest Medicines into a list and get an email when it puts out news.
Follow Everest Medicines